Shares Jump 28% on Reported $124/Share AstraZeneca Bid; NICE Expands IMCIVREE Access
RYTM sits 47% above its 52-week low of $74.5 on elevated volume (6.6× avg).
Summary
Rhythm shares rose 28% to $110.68 after a report that AstraZeneca offered about $124 per share, valuing the company at roughly $10 billion. Neither firm confirmed the report, so the entire move rests on an unconfirmed press account. The stock still trades well below the reported offer, which tells you the market is discounting the odds of a deal getting done. Separately, NICE expanded IMCIVREE guidance to cover adults with genetically confirmed Bardet-Biedl syndrome in England, Wales and Northern Ireland, enabling NHS-funded treatment — a real commercial expansion on top of the August UK authorization. This lands days after the $855 million LG Chem license-out and Q3 revenue of $92.1 million, up 80% year over year, so the fundamental story was already improving before the bid report.
At the time of this announcement, RYTM was trading at $109.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $74.50 to $122.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.